Hepatitis e in Germany-an under-reported infectious disease;Hepatitis E in Deutschland-eine unterschätzte Infektionskrankheit

Deutsches Arzteblatt International

Volumn 111, Issue 35-36, 2014, Pages 577-583+8+I

  Pischke, Sven ^a,d   Behrendt, Patrick ^a,c   Bock, Claus Thomas ^e   Jilg, Wolfgang ^f   Manns, Michael P ^a   Wedemeyer, Heiner ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Centre of Infection Research   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS E VACCINE; RIBAVIRIN;

ACUTE HEPATITIS; ACUTE LIVER FAILURE; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; BLOOD; BLOOD TRANSFUSION; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOOD INTAKE; GERMANY; GUILLAIN BARRE SYNDROME; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTIOUS HEPATITIS; LIVER CIRRHOSIS; MEDLINE; ORGAN TRANSPLANTATION; PORK; RAW FOOD; RETROSPECTIVE STUDY; TROPICAL DISEASE; VACCINATION; VIRUS TRANSMISSION; ADOLESCENT; AGED; CHILD; FEMALE; INFANT; MALE; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HEPATITIS E; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; RESEARCH DESIGN; RIBAVIRIN; RISK FACTORS; YOUNG ADULT;

EID: 84907522729     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0577     Document Type: Article

References (60)

1. Wedemeyer H, Pischke S, Manns MP: Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142: 1388-97.
2. Center for Disease Control and Prevention (CDC): Investigation of hepatitis E outbreak among refugees-Upper Nile, South Sudan, 2012-2013. MMWR Morb Mortal Wkly Rep 2013; 62: 581-6.
3. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST: The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2011; 55: 988-97.
4. Al-Shukri I, Davidson E, Tan A, et al.: Rash and arthralgia caused by hepatitis E. Lancet 2013; 382: 1856.
5. van den Berg B, Annemick A, Van der Eijk A, et al.: Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; epub ahead of print.
6. Pischke S, Heim A, Bremer B, et al.: Hepatitis E: An emerging infectious disease in Germany? Z Gastroenterol 2011; 49: 1255-7.
7. Wichmann O, Schimanski S, Koch J, et al.: Phylogenetic and casecontrol study on hepatitis E virus infection in Germany. J Infect Dis 2008; 198: 1732-41.
8. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; epub ahead of print.
9. Arbeitskreis Blut, Untergruppe .,Bewertung blutassoziierter Krankheitserreger": Hepatitis E Virus. Transfus Med Hemother 2009; 36: 40-7.
10. Faber MS, Wenzel JJ, Jilg W, et al.: Hepatitis E virus seroprevalence among adults, Germany. Emerg Infect Dis 2012; 18: 1654-7.
11. Christensen PB, Engle RE, Hjort C, et al.: Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis 2008; 47: 1026-31.
12. Ijaz S, Vyse AJ, Morgan D, et al.: Indigenous hepatitis E virus infection in England: more common than it seems. J Clin Virol 2009; 44: 272-6.
13. Said B, Ijaz S, Kafatos G, et al.: Hepatitis E outbreak on cruise ship. Emerg Infect Dis 2009; 15: 1738-44.
14. Zhu FC, Zhang J, Zhang XF, et al.: Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, rando-mised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.
15. Pischke S, Hardtke S, Bode U, et al.: Ribavirin treatment of acute and chronic hepatitis E: a single center experience. Liver Inter-national 2013; 33: 722-6.
16. Kamar N, Izopet J, Tripon S, et al.: Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-20.
17. Bose PD, Das BC, Kumar A, et al.: High viral load and deregulation of the progesterone receptor signaling pathway: Association with Hepatitis E-related poor pregnancy outcome. J Hepatol 2011; 54: 1107-13.
18. Baruah B, Bose PD, Ray C, et al.: Role of genetic alteration in MTHFR gene and homo-cysteine levles as critical factors influencing HEV related pregnancy outcome. Journal of Hepatology 2012; 56: 32-3.
19. González Tallón AI, Moreira Vicente V, Mateos Lindemann ML, Achécar Justo LM: Chronic hepatitis E in an immunocompetent patient. Gastroenterol Hepatol 2011; 34: 398-400.
20. Kamar N, Selves J, Mansuy JM, et al.: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-7.
21. Suneetha PV, Pischke S, Schlaphoff V, et al.: Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012; 55: 695-708.
22. Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J: How should hepatitis e virus infection be defined in organ-transplant recipients? Am J Transplant 2013; 13: 1935-6.
23. Kamar N, Garrouste C, Haagsma EB, et al.: Factors associated with chronic hepatitis in patients with hepatitis e virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-9.
24. Pischke S, Stiefel P, Franz B, et al.: Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012; 12: 3128-33.
25. Wang Y, Zhou X, Debing Y, et al.: Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014; 146: 1775-83.
26. Zhou X, Wang Y, Metselaar HJ, et al.: Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology 2014; epub ahead of print.
27. Pischke S, Suneetha PV, Baechlein C, et al.: Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010; 16: 74-82.
28. Haagsma EB, Niesters HG, van den Berg AP, et al.: Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15: 1225-8.
29. Pas SD, de Man RA, Mulders C, et al.: Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 2012; 18: 869-72.
30. Geng Y, Zhang H, Huang W, et al.: Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon 2014; 14: e15618.
31. Feldt T, Sarfo FS, Zoufaly A, et al.: Hepatitis E virus infections in HIVinfected patients in Ghana and Cameroon. J Clin Virol 2013; 58: 18-23.
32. Naik A, Gupta N, Goel D, et al.: Lack of evidence of hepatitis E virus infection among renal transplant recipients in a disease-endemic area. J Viral Hepat 2013; 20: e138-40.
33. Pischke S, Gisa A, Suneetha PV, et al.: Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One 2014; 9: e85330.
34. Junge N, Pischke S, Baumann U, et al.: Results of single-center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin. Pediatr Transplant 2013; 17: 343-7.
35. Baylis SA, Blumel J, Mizusawa S, et al.: World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis 2013; 19: 729-35.
36. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W: Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis 2013; 207: 497-500.
37. Schnegg A, Burgisser P, Andre C, et al.: An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PLoS One 2013; 8: e62980.
38. Zhang J, Zhang XF, Zhou C, et al.: Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity. Clin Microbiol Infect 2013; epub ahead of print.
39. Wu T, Zhu FC, Huang SJ, et al.: Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 2011; 55: 2038.
40. Emerson SU, Purcell RH: Running like water-the omnipresence of hepatitis E. N Engl J Med 2004; 351: 2367-8.
41. Wenzel JJ, Sichler M, Schemmerer M, et al.: Decline in hepatitis E virus antibody prevalence in Southeastern Germany, 1996-2011. Hepatology 2014; epub ahead of print.
42. le Coutre P, Meisel H, Hofmann J, et al.: Reactivation of hepatitis E infection in a patient with acute lymphoplastic leucemia after allogenic stem cell transplantation. Gut 2009; 58: 699-702.
43. Versluis J, Pasch SD, Agteresch HJ, et al.: Hepatitis e virus: an underestimated, opportunistic pathogen in recipientso of allogeneic hematopoietic stem cell transplantation. Blood 2013, 122; 1079-86.
44. Pischke S, Behrendt P, Manns MP, Wedemeyer H: HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infect Dis 2014; 8: 678-9.
45. Banks M, Bendall R, Grierson S, et al.: Human and porcine hepatitis E virus strains, United Kingdom. Emerg Infect Dis 2004; 10: 953-5.
46. Nelson KE: Transmission of hepatitis E virus by transfusion: what is the risk? Transfusion 2014; 54: 8-10.
47. Halac U, Beland K, Lapierre P, et al.: Chronic hepatitis E infection in children with liver transplantation. Gut 2011; 61: 597-603.
48. Teshale EH, Grytdal SP, Howard C, et al.: Evidence of person-toperson transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clin Infect Dis 2011; 50: 1006-10.
49. Schlosser B, Stein A, Neuhaus R, et al.: Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 2011; 56: 500-2.
50. van Eijk JJ, Madden RG, van der Eijk AA, et al.: Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014; 82: 498-503.
51. Kamar N, Weclawiak H, Guilbeau-Frugier C, et al.: Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012; 93: 617-23.
52. Kamar N, Bendall RP, Peron JM, et al.: Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17: 173-9.
53. Pischke S, Ho H, Urbanek F, et al.: Hepatitis E in HIV-positive patients in a low-endemic country. J Viral Hepat 2010; 17: 598-9.
54. Wenzel JJ, Preiss J, Schemmerer M, et al.: Detection of hepatitis E virus (HEV) from porcine livers in Southeastern Germany and high sequence homology to human HEV isolates. J Clin Virol 2011; 52: 50-4.
55. Krumbholz A, Mohn U, Lange J, et al.: Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs. Med Microbiol Immunol 2011; 201: 239-44.
56. Baylis SA, Koc O, Nick S, Blumel J: Widespread distribution of hepatitis E virus in plasma fractionation pools. Vox Sang 2011; 102: 182-3.
57. Pischke S, Horn-Wichmann R, Ernst D, et al.: Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients. Infect Dis Rep 2012; 4: e28.
58. Baylis SA, Gartner T, Nick S, Ovemyr J, Blumel J: Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang 2012; 103: 89-90.
59. Pischke S, Greer M, Hardtke S, et al.: Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. Transpl Infect Dis 2014; 16: 333-9.
60. Krumbholz A, Joel S, Dremsek P, et al.: Seroprevalence of hepatitis E virus (HEV) in humans living in high pig density areas of Germany. Med Microbiol Immunol 2014, 203: 273-82.